

Bit Market Services

Informazione Regolamentata n. 0472-12-2016	Data/Ora Ricezione 19 Febbraio 2016 09:56:23	MTA - Star
--	--	------------

Societa' : BB BIOTECH
Identificativo : 69693
Informazione
Regolamentata
Nome utilizzatore : BIOTECHNSS01 - Alderuccio
Tipologia : IRED 04
Data/Ora Ricezione : 19 Febbraio 2016 09:56:23
Data/Ora Inizio : 19 Febbraio 2016 10:11:24
Diffusione presunta
Oggetto : Ex dividend and payment date

Testo del comunicato

Vedi allegato.



Media release of 19 February 2016

Ex dividend and payment date

Schaffhausen – BB Biotech BoD will propose to the 22nd Annual General Meeting, which will be held on March 17 2016, to correspond, in place of a dividend, a cash distribution free of Swiss withholding tax of CHF 14.50 per share from paid-in capital reserves for around CHF 136 million, while the difference will be paid out as a regular dividend from retained earnings. Ex dividend date will be on March 21 2016, while the payment date will be on March 23 2016, with record date on March 22 2016.

For further information:

Investor Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00

Dr. Silvia Schanz, ssc@bellevue.ch

Maria-Grazia Iten-Alderuccio, mga@bellevue.ch

Claude Mikkelsen, cmi@bellevue.ch

Media Relations

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00

Tanja Chicherio, tch@bellevue.ch

b-public AG, Pfingstweidstrasse 6, 8005 Zürich, Switzerland, tel. +41 79 423 22 28

Thomas Egger, teg@b-public.ch

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with more than CHF 2.1 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Fine Comunicato n.0472-12

Numero di Pagine: 3